Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

1. πŸ’”πŸ©Έβš–οΈ Aspirin, Anticoagulants & Harm: Rethinking Dual Therapy in Stable CAD

4:23
 
Share
 

Manage episode 516050933 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

πŸ’ŠπŸ«€ Aspirin in the Crosshairs?

The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation.

πŸ“‰ Adding aspirin led to:

β€’ ↑ Ischemic events (HR 1.53; P=0.02)

β€’ ↑ Mortality (HR 1.72; P=0.01)

β€’ ↑ Major bleeding (HR 3.35; P<0.001)

🧠 Takeaway: More isn't always better. In high-risk CCS, aspirin may harm more than help.

πŸ“š Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

#Cardiology #Antiplatelet #NEJM #PrecisionMedicine #AQUATICTrial

  continue reading

753 episodes

Artwork
iconShare
 
Manage episode 516050933 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

πŸ’ŠπŸ«€ Aspirin in the Crosshairs?

The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation.

πŸ“‰ Adding aspirin led to:

β€’ ↑ Ischemic events (HR 1.53; P=0.02)

β€’ ↑ Mortality (HR 1.72; P=0.01)

β€’ ↑ Major bleeding (HR 3.35; P<0.001)

🧠 Takeaway: More isn't always better. In high-risk CCS, aspirin may harm more than help.

πŸ“š Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

#Cardiology #Antiplatelet #NEJM #PrecisionMedicine #AQUATICTrial

  continue reading

753 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play